WO2020248926A1 - 抗PDL1和TGFβ的双功能融合蛋白及其用途 - Google Patents
抗PDL1和TGFβ的双功能融合蛋白及其用途 Download PDFInfo
- Publication number
- WO2020248926A1 WO2020248926A1 PCT/CN2020/094855 CN2020094855W WO2020248926A1 WO 2020248926 A1 WO2020248926 A1 WO 2020248926A1 CN 2020094855 W CN2020094855 W CN 2020094855W WO 2020248926 A1 WO2020248926 A1 WO 2020248926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- fusion protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Definitions
- the invention relates to the field of biomedicine or biopharmaceutical technology. Specifically, the present invention relates to anti-PDL1 antibodies, anti-PDL1 and TGF ⁇ bifunctional fusion proteins and variants and antigen-binding fragments thereof, as well as methods for their preparation and methods and uses for the treatment of cancer.
- PD1 programmed cell death-1
- PDL1 programmed cell death-1 ligand 1
- PD1 is expressed on the surface of activated T cells and NK cells, and tumor cells pass a large number of Express PDL1, inhibit the maturation and proliferation of T cells and NK cells after binding to PD1, and escape immune surveillance (Iwai et al., PNAS99: 12293-7, 2002) (Ohigashi et al., Clin Cancer Res 11: 2947-53 ,2005). Therefore, blocking the interaction between the two can reactivate T cells, recognize and kill tumor cells, and benefit patients.
- TGF ⁇ can inhibit the growth of early tumors, but as the tumor continues to progress, tumor cells become less sensitive to TGF ⁇ . At this time, TGF ⁇ promotes tumor growth by promoting epithelial-stromal metastasis and suppressing the immune system (Bierie et ah , Nat Rev Cancer. 2006; 6:506-20).
- TGF ⁇ RII The extracellular domain of TGF ⁇ RII is only 136 amino acid residues long and can bind to TGF ⁇ 1 (Lin et al, J Biol Chem. 1995; 270: 2747-54). Soluble TGF ⁇ RII-Fc has been tested as an anticancer agent, and it has been shown to inhibit the growth of malignant mesothelioma in a mouse model (Suzuki et al, Clin Cancer Res. 2004; 10: 5907-18) (Suzuki et al., Clin Cancer) Res. 2004; 10:5907-18).
- Merck's M7824 bifunctional fusion protein (Chinese application number CN201580007865.3) is an anti-PDL1 antibody Avelumab and TGF ⁇ RII connected through (G 4 S) 4 G. It has completed some phase I and phase II clinical trials and has been used in a variety of solid tumors. Performs well in the medium (MSB0011359C).
- VL light chain variable region
- VH heavy chain variable region
- LCDR light chain complementarity determining region
- HCDR heavy chain complementarity determining region
- LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 The various embodiments of HCDR3 and HCDR3 can be implemented individually or in any combination.
- the present invention relates to an antibody or its antigen binding fragment or bifunctional fusion protein and its preparation method and application.
- the present invention relates to antibodies or antigen-binding fragments thereof, comprising three heavy chain complementarity determining regions, wherein the HCDR1 amino acid sequence is shown in SEQ ID NO: 8 and the HCDR2 amino acid sequence is shown in SEQ ID NO: 9
- the amino acid sequence of HCDR3 is shown in SEQ ID NO: 10.
- the antibody or antigen-binding fragment thereof further comprises three light chain complementarity determining regions, wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO: 5, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 6, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 7 is shown.
- the antibody or antigen-binding fragment thereof provided by the present invention includes the heavy chain variable region shown in SEQ ID NO: 2; preferably, it also contains the light chain variable region shown in SEQ ID NO:1.
- the present invention relates to an antibody or an antigen-binding fragment thereof, comprising three light chain complementarity determining regions, wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO: 11, and the amino acid sequence of LCDR2 is shown in SEQ ID NO: 6
- the amino acid sequence of LCDR3 is shown in SEQ ID NO: 12; and/or three heavy chain complementarity determining regions, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO: 13, and the amino acid sequence of HCDR2 is shown in SEQ ID NO: 14, and HCDR3
- the amino acid sequence is shown in SEQ ID NO: 15.
- the present invention relates to an antibody or antigen-binding fragment thereof comprising the light chain variable region of the amino acid sequence shown in SEQ ID NO: 3, and/or the heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 4.
- sequence of the light chain constant region of the antibody or antigen-binding fragment thereof in any of the foregoing aspects is SEQ ID NO: 16.
- sequence of the heavy chain constant region of the antibody or antigen-binding fragment thereof in any of the foregoing aspects is SEQ ID NO: 17.
- the antibody or antigen-binding fragment thereof provided by the present invention preferably comprises the light chain variable region of the amino acid sequence shown in SEQ ID NO: 1, and the heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: The light chain constant region of the amino acid sequence shown in: 16 and the heavy chain constant region of the amino acid sequence shown in SEQ ID NO: 17.
- the antibody or antigen-binding fragment thereof provided by the present invention preferably comprises the light chain variable region of the amino acid sequence shown in SEQ ID NO: 3, and the heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 4, SEQ ID NO: The light chain constant region of the amino acid sequence shown in 16 and the heavy chain constant region of the amino acid sequence shown in SEQ ID NO: 17.
- the present invention relates to the antibody or antigen-binding fragment thereof according to any one of the foregoing aspects, including monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, Fab, Fab', F(ab')2 , Fv, scFv or dsFv fragments, etc.
- any of the aforementioned antibodies or antigen-binding fragments thereof bind to PDL1.
- the present invention relates to a bifunctional fusion protein, which comprises the antibody or antigen-binding fragment thereof according to any one of the foregoing aspects, and a TGF ⁇ RII fragment.
- the TGF ⁇ RII fragment comprises the extracellular domain of TGF ⁇ RII.
- the antibody or antigen-binding fragment thereof in any one of the foregoing aspects is connected to the TGF ⁇ RII fragment through a linker.
- the TGF ⁇ RII fragment is connected to the antibody or antigen-binding fragment thereof.
- the C-terminus of the heavy chain constant region of the fragment is preferably connected by a (G 4 S) 4 G (ie GGGGSGGGGSGGGGSGGGGSG) linker.
- the sequence of the heavy chain constant region of the bifunctional fusion protein is SEQ ID NO: 22, preferably Specifically, the sequence of the TGF ⁇ RII fragment of the bifunctional fusion protein is SEQ ID NO: 23; specifically, the structure of the bifunctional fusion protein is: an antibody or an antigen-binding fragment thereof-(G 4 S) 4 G-TGF ⁇ RII fragment.
- the sequence of the light chain variable region of the antibody or antigen-binding fragment thereof is SEQ ID NO: 1
- the sequence of the heavy chain variable region is SEQ ID NO: 2
- the sequence of the constant region of the light chain is SEQ ID NO: 16
- the sequence of the constant region of the heavy chain is SEQ ID NO: 22
- the sequence of the TGF ⁇ RII fragment is SEQ ID NO: 23; specifically The sequence where the heavy chain constant region and the TGF ⁇ RII fragment are connected via (G 4 S) 4 G is SEQ ID NO: 18.
- the sequence of the light chain variable region of the antibody or antigen-binding fragment thereof is SEQ ID NO: 3
- the sequence of the heavy chain variable region is SEQ ID NO: 4
- the sequence of the constant region of the light chain is SEQ ID NO: 16
- the sequence of the constant region of the heavy chain is SEQ ID NO: 22
- the sequence of the TGF ⁇ RII fragment is SEQ ID NO: 23; specifically The sequence where the heavy chain constant region and the TGF ⁇ RII fragment are connected via (G 4 S) 4 G is SEQ ID NO: 18.
- any one of the above-mentioned bifunctional fusion proteins binds PDL1 and TGF ⁇ .
- the present invention relates to a nucleic acid that encodes the antibody or antigen-binding fragment or bifunctional fusion protein of any one of the foregoing aspects.
- the present invention relates to a vector comprising the nucleic acid described in the previous aspect, or it can express the antibody or antigen-binding fragment or bifunctional fusion protein of any one of the foregoing aspects.
- the vector can be a viral vector; preferably, the viral vector includes, but is not limited to, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a retroviral vector; preferably, the vector can be a non-viral vector Vector;
- the vector can be a mammalian expression vector; preferably, the expression vector can be a bacterial expression vector; preferably, the expression vector can be a fungal expression vector.
- the present invention relates to a cell that can express the antibody or antigen-binding fragment or bifunctional fusion protein of any one of the foregoing aspects.
- the cell is a bacterial cell; preferably, the bacterial cell is an E. coli cell, etc.; preferably, the cell is a fungal cell; preferably, the fungal cell is a yeast cell; preferably, the yeast
- the cells are Pichia pastoris cells, etc.; preferably, the cells are mammalian cells; preferably, the mammalian cells are Chinese hamster ovary cells (CHO), human embryonic kidney cells (293), B cells, T cells, DC cells or NK cells, etc.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, bifunctional fusion protein, nucleic acid, carrier or cell according to any one of the foregoing aspects.
- the pharmaceutical composition also Contains pharmaceutically acceptable excipients, preferably, the pharmaceutically acceptable excipients include one or more of the following: pharmaceutically acceptable solvents, dispersants, additives, plasticizers, etc. .
- the pharmaceutical composition may also contain other therapeutic agents.
- other therapeutic agents include chemotherapeutic agents, immunotherapeutic agents, or hormone therapy agents. The combined administration of the antibody or antigen-binding fragment and other therapeutic agents can enhance the therapeutic effect.
- the "enhancement of the therapeutic effect” refers to enhancing the therapeutic effect of other therapeutic agents or therapies.
- the antibody or antigen-binding fragment provided by the present invention can be administered alone or in combination with other therapeutic agents or therapies.
- other therapeutic agents or therapies include chemotherapeutic agents, immunotherapeutic agents, hormone therapy agents, radiation therapy, surgical treatment.
- kits comprising the antibody or antigen-binding fragment thereof of the present invention, or a bifunctional fusion protein, or a nucleic acid encoding the antibody or antigen-binding fragment or bifunctional fusion protein.
- the present invention relates to the use of the antibody or antigen-binding fragment, bifunctional fusion protein, nucleic acid, carrier or cell of any one of the foregoing aspects in the preparation of drugs for treating or preventing diseases.
- the present invention relates to the use of the antibody or antigen-binding fragment, bifunctional fusion protein or nucleic acid of any one of the foregoing aspects in the preparation of a diagnostic or detection kit.
- a method for treating or preventing diseases comprising administering the antibody or antigen-binding fragment, bifunctional fusion protein, nucleic acid, carrier, cell or pharmaceutical composition of any aspect of the present invention to a recipient in need Examiner.
- a method of diagnosis or detection comprising administering the antibody or antigen-binding fragment, bifunctional fusion protein, nucleic acid or kit of any aspect of the present invention to a subject or sample in need.
- the method is a method of diagnosing or detecting a disease.
- the present invention relates to the use of the antibody or antigen-binding fragment, bifunctional fusion protein, nucleic acid, carrier, cell or pharmaceutical composition of any one of the foregoing aspects for the treatment or prevention of diseases.
- the present invention relates to the use of the antibody or antigen-binding fragment, bifunctional fusion protein, nucleic acid or kit of any one of the foregoing aspects for detection or diagnosis.
- the use is for diagnosing or detecting diseases.
- the disease is cancer.
- the cancer includes gastric cancer, esophageal cancer, head and neck cancer, bladder cancer, cervical cancer, sarcoma, cell tumor, lung cancer, colon cancer, ovarian cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, melanin Tumors, breast cancer, myeloma, glioma, leukemia, lymphoma, etc.
- the present invention relates to a method for preparing the antibody or antigen-binding fragment or bifunctional fusion protein of any one of the foregoing aspects, comprising transfecting cells with the above-mentioned vector, and expressing the antibody or the antibody or its An antigen-binding fragment or a bifunctional fusion protein; or including the expression of the antibody or an antigen-binding fragment or a bifunctional fusion protein with the aforementioned cells.
- the antibody or antigen-binding fragment or bifunctional fusion protein provided by the present invention has one or more of the following advantages: enhanced TGF ⁇ 1 binding activity, enhanced PDL1 affinity, enhanced ability to block the binding of PDL1 and PD1, and enhanced blocking of TGF ⁇ 1 Functional activity, enhanced ability to promote T cells to secrete IFN- ⁇ , better immune regulation effect, and better tumor suppression effect.
- Figure 1 shows the serum titers of BoAn-hMab1 mice after five immunizations (2500-fold dilution).
- Figure 2 shows the binding of the bifunctional fusion protein to the TGF ⁇ 1 protein.
- Figure 3 shows that the bifunctional fusion protein promotes the secretion of IFN- ⁇ from CD4+T.
- Figure 4 shows the blocking effect of the bifunctional fusion protein on TGF ⁇ 1 function.
- Figure 5A shows the body weight of the MC38-hPD-L1 tumor model mouse
- Figure 5B shows the tumor volume of the MC38-hPD-L1 tumor model mouse
- Figure 5C shows the tumor weight of the MC38-hPD-L1 tumor model mouse.
- PDL1 protein (Sinobiological, catalog number: 10084-H08H); PD1 protein (Sinobiological, catalog number: 10377-H08H); TGF ⁇ 1 (Sinobiological, catalog number: 10804-HNAC); NaHCO 3 (Sinobiological, 10018960); TMB (Beijing Meikewande, catalog number: 1001); STREP/HRP (R&D, catalog number: 890803); HBS-EP+1 ⁇ buffer (GE, catalog number: BR-1008-26); microtiter plate (Suzhou Beaver, catalog number: 40301); biosensor chip (GE, catalog number: BR100530); 96-well round bottom plate (Corning, catalog number: 3799); anti-human IgG Fc amino coupling kit (GE, cat#BR -1008-39);
- the serum titer (2500-fold dilution) detected by ELISA is shown in Figure 1.
- PL1Q15, PL1Q16, PL1Q18, PL1Q19, PL1Q21 mice are Freund's adjuvant immunized mice
- PL1Q24 mice are gold adjuvant immunized mice.
- spleens Six mice with a higher serum titer in 1.1 were sacrificed, the spleens were dissected, and the spleens were ground and broken with a syringe rubber stopper and filtered with a strainer (FALCON, catalog number: 352350). The filtered spleen cells were frozen for later use. After RNA is extracted, cDNA is obtained by reverse transcription. The establishment of the phage library is carried out according to the method described in Carlos F. Barbas III, Phage display: A laboratory manual, and the variable regions of the heavy and light chains are obtained from the cDNA by PCR. , And then the variable regions of the heavy and light chains were obtained by overlapping extension PCR to obtain single-chain Fv (scFv).
- scFv single-chain Fv
- the scFv was digested with SfiI enzyme (NEB, catalog number: #R0123L) and then passed through T4DNA ligase (Yiqiao Shenzhou). ) Was ligated with plasmid pCOMB3x (China Plasmid Vector Strain Cell Line Gene Collection Center, BIOVECTOR510837), and then the ligated product was electrotransfected into E. coli TG1 competent cells (Lucigen, catalog number: A96595-2), and the transfected TG1 After culturing on a shaker at 37°C and 220 rpm, phage infection was added, and then the culture supernatant was recovered and purified to obtain a phage library.
- SfiI enzyme NEB, catalog number: #R0123L
- T4DNA ligase Yamaqiao Shenzhou
- Magnetic bead screening Biotinylate PDL1-mFc protein (Acrobiosystems, catalog number: PD1-H52A3) (the molar ratio of protein to biotin is 1:2): Change the PDL1-mFc protein to 0.1M pH8.0NaHCO 3 In the medium, a precision balance weighs an appropriate amount of biotin (Thermo, 21335) and dissolves it in ultrapure water, immediately adds an appropriate amount of dissolved biotin to the PDL1-mFc protein solution, and incubates on a rotating mixer in the dark for 40 minutes. After the labeling is completed Change the PDL1-mFc protein solution to PBS.
- Phage clones express scFv in Escherichia coli, and then detect the blocking of PDL1/PD1 binding by scFv by ELISA, and clones that retain the blocking activity for subsequent molecular construction.
- ELISA detection of scFv blocking the binding of PD1/PDL1 Dilute PD1 protein to 0.5 ⁇ g/mL with pH9.6CBS, coat the ELISA plate, 100 ⁇ L/well, incubate at 4°C overnight; wash the plate with 3% skimmed milk powder at 37°C Closed for 1h. After washing the plate, add 50 ⁇ L of scFv periplasm to each well.
- biotin-labeled PDL1-Fc protein final concentration 0.2 ⁇ g/mL
- STREP/HRP diluted with PBST
- 100 ⁇ L/well 100 ⁇ L/well
- incubate at 37°C for 1h.
- the magnetic beads screened clones BA533, BA603, BT613, BA623, BA649, BA669, BA466 and the plate screened clone BA705 were sent to Invitrogen Biotechnology Co., Ltd. for sequencing.
- the amino acid sequences of each cloned light chain variable region and heavy chain variable region are listed in Table 1.
- nucleotide sequence encoding VH into the vector pCDNA3.4 (Life Technology) with the nucleotide sequence encoding SEQ ID NO: 18, wherein SEQ ID NO: 18 contains The heavy chain constant region sequence and TGF ⁇ RII sequence of the IgG1 antibody linked by (G 4 S) 4 G, the nucleotide sequence encoding VL is inserted into the amino acid sequence encoding the antibody light chain constant region (SEQ ID NO: 16) Nucleotide sequence vector pCDNA3.4 (Life Technology), then transfected HEK293 cells, and cultured in a shaker at 37°C ⁇ 8%CO 2 ⁇ 125rpm for 6-7 days,
- the amino acid sequence of the variable region of Avelumab of Merck was determined by IMGT database (the sequence of the variable region of the heavy chain is SEQ ID NO: 19, and the sequence of the variable region of the light chain is SEQ ID NO: 20), and the entire gene is synthesized and inserted into the vector pCDNA3 .4, expressed by HEK293 cells, and the purified bifunctional fusion protein was named PLTGB-M7824-IgG1 (heavy chain variable region sequence is SEQ ID NO: 19, light chain variable region sequence is SEQ ID NO: 20, light The sequence of the chain constant region is SEQ ID NO: 21, and the sequence of the heavy chain constant region and TGF ⁇ RII is SEQ ID NO: 18).
- TGF ⁇ 1 Dilute TGF ⁇ 1 with pH9.6CBS to different concentrations (0.2 ⁇ g/mL, 0.05 ⁇ g/mL, 0.0125 ⁇ g/mL), respectively coat the ELISA plate, 100 ⁇ L/well, incubate at 4°C overnight; wash the plate with 3% skimmed milk powder Block at 37°C for 1h; after washing the plate, add 100 ⁇ L of candidate bifunctional fusion protein (1 ⁇ g/mL) diluted in PBST (PBS+0.05% Tween20) to each well, incubate at 37°C for 1h; then add goat anti-human IgG/HRP and incubate at 37°C 1h; After washing the plate, add TMB for color development, add 50 ⁇ L 2M H 2 SO 4 to each well for 10 minutes to stop color development, and read OD450 on the microplate reader.
- Table 3 and Figure 2 The results are shown in Table 3 and Figure 2.
- the OD values of the candidate bifunctional fusion proteins PLTGBQ19-BA533-IgG1, PLTGBQ21-BA669-IgG1 at each concentration are higher than those of the control group PLTGB-M7824-IgG1, indicating that the candidate bifunctional fusion protein has a better effect on TGF ⁇ 1 Binding capacity.
- Purify by size exclusion chromatography (Shanghai Bogelong, catalog number: AG319109): equilibrate the column with 1.5CV buffer, load the sample, the sample volume is not more than 3% CV, continue to rinse with buffer, and collect after peaking Objective Bifunctional fusion protein.
- IFN- ⁇ secretion values of candidate bifunctional fusion proteins PLTGBQ19-BA533-IgG1 and PLTGBQ21-BA669-IgG1 at the same concentration were higher than those of the control group PLTGB-M7824-IgG1.
- the candidate bifunctional fusion protein PLTGBQ19-BA533-IgG1, PLTGBQ21-BA669-IgG1 may have better immune regulation and anti-tumor properties than the control group PLTGB-M7824-IgG1.
- the antibody binding kinetics was detected by BIAcore8K instrument.
- the anti-human IgG antibody was coupled to the CM5 biosensor chip by the anti-human IgG Fc amino coupling kit to obtain about 1000 RU (response unit). Dilute PDL1 with HBS-EP+1 ⁇ buffer to 50nM, and then dilute it twice, for a total of 5 concentrations (50nM, 25nM, 12.5nM, 6.25nM, 3.125nM), and set a blank control.
- the determination steps and conditions are as follows: bifunctional fusion protein injection 2 ⁇ g/mL, injection time 70s, flow rate 5 ⁇ L/min, stable for 5s; PDL1 protein binding and dissociation: binding 60s, flow rate 30 ⁇ L/min, dissociation 450s; regeneration: Regenerate with 3M MgCl 2 buffer solution for 30 seconds and start 3 times.
- a one-to-one Languir model (BIAcore Evaluation Software version 3.2) was used to calculate the binding constant (ka) and dissociation constant (kd), and the equilibrium dissociation constant KD was calculated from kd/ka.
- the affinity data of each bifunctional fusion protein is shown in Table 5.
- MV-1-Lu cells were resuspended on the basis and added to a white 96-well plate (Corning, catalog number: 3917), 50 ⁇ L/well, 2000 cells/well. Dilute the bifunctional fusion protein to 333.3 ng/mL with complete medium, and then sequentially dilute it by 3 times to a total of 6 concentrations, and add it to the cell wells at 25 ⁇ L/well.
- TGF ⁇ 1 Dilute TGF ⁇ 1 to 2ng/mL with complete medium and add it to cell wells at 25 ⁇ L/well.
- the final concentration of the bifunctional fusion protein 83.3ng/mL, 27.8ng/mL, 9.26ng/mL, 3.09ng/mL, 1.03ng/mL, 0.34ng/mL.
- the CellTiter-Glo kit Promega, catalog number: G7571 was used to detect the fluorescence value in the 96-well plate (the fluorescence value can represent the number of cells).
- the candidate bifunctional fusion proteins PLTGBQ19-BA533-IgG1 and PLTGBQ21-BA669-IgG1 have better activity to block the function of TGF ⁇ 1 than the control group PLTGB-M7824-IgG1.
- the candidate bifunctional fusion protein PLTGBQ19-BA533-IgG1, PLTGBQ21-BA669-IgG1 can better block the TGF pathway than the control group PLTGB-M7824-IgG1, and have better immune regulation and anti-tumor properties.
- the IgG1 monoclonal antibody corresponding to the bifunctional fusion protein was constructed.
- the monoclonal antibody corresponding to PLTGBQ19-BA533-IgG1 is BA533-IgG1 (the heavy chain variable region sequence is SEQ ID NO: 2, and the light chain variable region sequence is SEQ ID NO:1
- the light chain constant region sequence is SEQ ID NO: 16, the heavy chain constant region sequence is SEQ ID NO: 17);
- the corresponding monoclonal antibody of PLTGBQ21-BA669-IgG1 is BA669-IgG1 (the heavy chain variable region sequence is SEQ ID NO: 4
- the light chain variable region sequence is SEQ ID NO: 3, the light chain constant region sequence is SEQ ID NO: 16, and the heavy chain constant region sequence is SEQ ID NO: 17);
- PLTGB-M7824-IgG1 corresponding monoclonal antibody is Avelumab ( The heavy chain variable region sequence is SEQ ID NO: 19, the light chain variable region sequence is SEQ ID
- Mouse colon cancer MC38-hPD-L1 cells were purchased from Beijing Biocytogen Biotechnology Co., Ltd.
- the culture conditions were DMEM (Gibco, catalog number: 11965-092) medium plus 10% FBS (Gibco, catalog number: 10099-141C), 1% P/S (Gibco, catalog number: 15070-063), 37°C , 5% CO 2 incubator culture. Passage 2-3 times a week.
- Collect MC38-hPD-L1 cells in good condition resuspend them in PBS and adjust the cell concentration to 5 ⁇ 10 6 /ml, and inoculate 0.1 ml of cell suspension subcutaneously on the dorsal side of the forelimb of each mouse. Randomization was started when the average tumor volume reached 87mm 3 . There are 7 groups, 6 animals in each group. The administration was started on the day of grouping. The anti-PD-L1 monoclonal antibody was diluted with PBS. Two doses of each antibody: 3mg/kg and 10mg/kg, intraperitoneal injection, once every 2 days, The solvent control group was given the same volume of PBS as a control.
- the candidate antibody has better anti-tumor effect than the control antibody, and high doses also have comparable anti-tumor effect.
- group End point tumor weight (g) Vehicle(Q2D,i.p.) 2.12 ⁇ 0.24 BA533-IgG1 (3mg/kg, Q2D, i.p.) 0.92 ⁇ 0.26 BA669-IgG1 (3mg/kg, Q2D, i.p.) 0.77 ⁇ 0.13 Avelumab (3mg/kg, Q2D, i.p.) 1.22 ⁇ 0.33 BA533-IgG1 (10mg/kg, Q2D, i.p.) 0.46 ⁇ 0.12 BA669-IgG1 (10mg/kg, Q2D, i.p.) 0.39 ⁇ 0.08 Avelumab (10mg/kg, Q2D, i.p.) 0.42 ⁇ 0.09
Abstract
Description
PLTGBQ19-BA533-IgG1 | PLTGBQ24-BA603-IgG1 | PLTGBQ16-BA466-IgG1 |
PLTGBQ21-BA649-IgG1 | PLTGBH03-BT613-IgG1 | PLTGBQ24-BA705-IgG1 |
PLTGBQ21-BA669-IgG1 | PLTGBQ21-BA623-IgG1 | / |
名称 | ka(1/Ms) | kd(1/s) | KD(M) |
PLTGBQ16-BA466-IgG1 | 1.14E+06 | 2.32E-03 | 2.03E-09 |
PLTGBQ19-BA533-IgG1 | 1.50E+06 | 7.95E-04 | 5.29E-10 |
PLTGBQ24-BA603-IgG1 | 1.70E+06 | 1.64E-03 | 9.63E-10 |
PLTGBQ21-BA623-IgG1 | 1.34E+06 | 1.79E-03 | 1.34E-09 |
PLTGBQ21-BA649-IgG1 | 1.85E+06 | 1.67E-03 | 9.04E-10 |
PLTGBQ21-BA669-IgG1 | 1.78E+06 | 1.36E-03 | 7.64E-10 |
PLTGBQ24-BA705-IgG1 | 1.45E+06 | 8.37E-04 | 5.77E-10 |
PLTGBH03-BT613-IgG1 | 1.39E+06 | 1.01E-03 | 7.30E-10 |
PLTGB-M7824-IgG1 | 4.98E+05 | 3.00E-04 | 6.03E-10 |
组 | 重点肿瘤体积(mm 3) |
Vehicle(Q2D,i.p.) | 1972±224 |
BA533-IgG1(3mg/kg,Q2D,i.p.) | 780±185 |
BA669-IgG1(3mg/kg,Q2D,i.p.) | 679±113 |
Avelumab(3mg/kg,Q2D,i.p.) | 969±208 |
BA533-IgG1(10mg/kg,Q2D,i.p.) | 465±131 |
BA669-IgG1(10mg/kg,Q2D,i.p.) | 392±83 |
Avelumab(10mg/kg,Q2D,i.p.) | 408±90 |
组 | 终点瘤重(g) |
Vehicle(Q2D,i.p.) | 2.12±0.24 |
BA533-IgG1(3mg/kg,Q2D,i.p.) | 0.92±0.26 |
BA669-IgG1(3mg/kg,Q2D,i.p.) | 0.77±0.13 |
Avelumab(3mg/kg,Q2D,i.p.) | 1.22±0.33 |
BA533-IgG1(10mg/kg,Q2D,i.p.) | 0.46±0.12 |
BA669-IgG1(10mg/kg,Q2D,i.p.) | 0.39±0.08 |
Avelumab(10mg/kg,Q2D,i.p.) | 0.42±0.09 |
Claims (10)
- 一种抗体或其抗原结合片段,所述抗体或其抗原结合片段包含3个重链互补决定区,其中,HCDR1氨基酸序列如SEQ ID NO:8所示,HCDR2氨基酸序列如SEQ ID NO:9所示,HCDR3氨基酸序列如SEQ ID NO:10所示。
- 根据权利要求1所述的抗体或其抗原结合片段,还包含3个轻链互补决定区,其中,LCDR1氨基酸序列如SEQ ID NO:5所示,LCDR2氨基酸序列如SEQ ID NO:6所示,LCDR3氨基酸序列如SEQ ID NO:7所示。
- 一种抗体或其抗原结合片段,所述抗体或其抗原结合片段包含SEQ ID NO:2所示的重链可变区;优选还含有SEQ ID NO:1所示的轻链可变区。
- 根据权利要求1-3中任一项所述的抗体或其抗原结合片段,所述抗原结合片段包括单克隆抗体、多克隆抗体、嵌合抗体、人源化抗体、Fab、Fab’、F(ab’)2、Fv、scFv或dsFv片段。
- 根据权利要求1-4中任一项所述的抗体或其抗原结合片段,所述抗体或其抗原结合片段结合PDL1。
- 一种双功能融合蛋白,所述双功能融合蛋白包括根据权利要求1-5中任一项所述的抗体或其抗原结合片段,以及TGFβRII片段,所述抗体或其抗原结合片段与所述TGFβRII片段通过接头连接。
- 一种核酸或细胞,所述核酸编码根据权利要求1-5任一项所述的抗体或其抗原结合片段,或根据权利要求6所述的双功能融合蛋白,所述细胞表达根据权利要求1-5任一项所述的抗体或其抗原结合片段,或根据权利要求6所述的双功能融合蛋白。
- 一种药物组合物,其包含根据权利要求1-5中任一项所述的抗体或其抗原结合片段,或根据权利要求6所述的双功能融合蛋白,或根据权利要求7所述的核酸或细胞。
- 一种试剂盒,其包含根据权利要求1-5中任一项所述的抗体或其抗原结合片段,或根据权利要求6所述的双功能融合蛋白,或根据权利要求7所述的核酸。
- 根据权利要求1-5中任一项所述的抗体或其抗原结合片段,或根据权利要求6所述的双功能融合蛋白,或权利要求7所述的核酸用于治疗、预防、检测或诊断疾病的用途,优选地,所述疾病是癌症;更优选为胃癌、食道癌、头颈癌、膀胱癌、***、肉瘤、细胞瘤、肺癌、结肠癌、卵巢癌、肾脏癌、结肠直肠癌、胰脏癌、肝癌、黑色素瘤、乳腺癌、骨髓瘤、神经胶质瘤、白血病和淋巴瘤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021560523A JP7297090B2 (ja) | 2019-06-10 | 2020-06-08 | PDL1及びTGFβに対する二機能性融合タンパク質並びにその使用 |
EP20822451.9A EP3929215A4 (en) | 2019-06-10 | 2020-06-08 | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE |
BR112021024820A BR112021024820A2 (pt) | 2019-06-10 | 2020-06-08 | Proteína de fusão bifuncional contra pdl1 e tgfss e uso da mesma |
KR1020217040151A KR20220007118A (ko) | 2019-06-10 | 2020-06-08 | PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도 |
CN202080000954.6A CN114206926B (zh) | 2019-06-10 | 2020-06-08 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
AU2020290119A AU2020290119A1 (en) | 2019-06-10 | 2020-06-08 | Bifunctional fusion protein against PDL1 and TGFβ and use thereof |
CA3135988A CA3135988A1 (en) | 2019-06-10 | 2020-06-08 | Bifunctional fusion protein against pdl1 and tgf.beta. and use thereof |
US17/601,891 US20220213195A1 (en) | 2019-06-10 | 2020-06-08 | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFß AND USE THEREOF |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910497064 | 2019-06-10 | ||
CN201910497723 | 2019-06-10 | ||
CN201910497064.X | 2019-06-10 | ||
CN201910497723.X | 2019-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020248926A1 true WO2020248926A1 (zh) | 2020-12-17 |
Family
ID=73780650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/094855 WO2020248926A1 (zh) | 2019-06-10 | 2020-06-08 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220213195A1 (zh) |
EP (1) | EP3929215A4 (zh) |
JP (1) | JP7297090B2 (zh) |
KR (1) | KR20220007118A (zh) |
CN (1) | CN114206926B (zh) |
AU (1) | AU2020290119A1 (zh) |
BR (1) | BR112021024820A2 (zh) |
CA (1) | CA3135988A1 (zh) |
WO (1) | WO2020248926A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063526A (zh) * | 2022-12-31 | 2023-05-05 | 合肥天港免疫药物有限公司 | 抗pdl1的抗体及其用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3990116A1 (en) * | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
CN115175942A (zh) * | 2020-02-25 | 2022-10-11 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103571872A (zh) | 2012-08-09 | 2014-02-12 | 山东国际生物科技园发展有限公司 | 一种能够表达人抗体的转基因动物的制备方法 |
CN106103488A (zh) * | 2014-02-10 | 2016-11-09 | 默克专利有限公司 | 靶向TGFβ抑制 |
WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
CN109641963A (zh) * | 2016-08-12 | 2019-04-16 | 默克专利有限公司 | 癌症的联合治疗 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
KR101573109B1 (ko) * | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
CN115093480A (zh) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
CU20170052A7 (es) * | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
MX2019013023A (es) * | 2017-05-12 | 2019-12-18 | Jiangsu Hengrui Medicine Co | Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma. |
EP3630148A4 (en) * | 2017-05-26 | 2021-06-16 | The Johns Hopkins University | MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS FOR THE MODULATION OF IMMUNTOLERANCE |
WO2019101196A1 (zh) * | 2017-11-27 | 2019-05-31 | 山东博安生物技术有限公司 | 抗pd-l1的抗体及其用途 |
-
2020
- 2020-06-08 CN CN202080000954.6A patent/CN114206926B/zh active Active
- 2020-06-08 EP EP20822451.9A patent/EP3929215A4/en active Pending
- 2020-06-08 CA CA3135988A patent/CA3135988A1/en active Pending
- 2020-06-08 US US17/601,891 patent/US20220213195A1/en active Pending
- 2020-06-08 JP JP2021560523A patent/JP7297090B2/ja active Active
- 2020-06-08 WO PCT/CN2020/094855 patent/WO2020248926A1/zh unknown
- 2020-06-08 KR KR1020217040151A patent/KR20220007118A/ko unknown
- 2020-06-08 BR BR112021024820A patent/BR112021024820A2/pt unknown
- 2020-06-08 AU AU2020290119A patent/AU2020290119A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103571872A (zh) | 2012-08-09 | 2014-02-12 | 山东国际生物科技园发展有限公司 | 一种能够表达人抗体的转基因动物的制备方法 |
CN106103488A (zh) * | 2014-02-10 | 2016-11-09 | 默克专利有限公司 | 靶向TGFβ抑制 |
CN109641963A (zh) * | 2016-08-12 | 2019-04-16 | 默克专利有限公司 | 癌症的联合治疗 |
WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
Non-Patent Citations (7)
Title |
---|
BIERIE ET AL., NAT REV CANCER, vol. 6, 2006, pages 506 - 20 |
IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7 |
LIN ET AL., J BIOL CHEM., vol. 270, 1995, pages 2747 - 54 |
OHIGASHI ET AL., CLIN CANCER RES, vol. 11, 2005, pages 2947 - 53 |
See also references of EP3929215A4 |
SUZUKI ET AL., CLIN CANCER RES, vol. 10, 2004, pages 5907 - 18 |
SUZUKI ET AL., CLIN CANCER RES., vol. 10, 2004, pages 5907 - 18 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063526A (zh) * | 2022-12-31 | 2023-05-05 | 合肥天港免疫药物有限公司 | 抗pdl1的抗体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3135988A1 (en) | 2020-12-17 |
JP2022528007A (ja) | 2022-06-07 |
CN114206926B (zh) | 2022-06-17 |
JP7297090B2 (ja) | 2023-06-23 |
CN114206926A (zh) | 2022-03-18 |
AU2020290119A1 (en) | 2021-10-07 |
EP3929215A4 (en) | 2022-06-22 |
BR112021024820A2 (pt) | 2022-01-25 |
EP3929215A1 (en) | 2021-12-29 |
KR20220007118A (ko) | 2022-01-18 |
US20220213195A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI796328B (zh) | B7-h3抗體、其抗原結合片段及其醫藥用途 | |
WO2020248926A1 (zh) | 抗PDL1和TGFβ的双功能融合蛋白及其用途 | |
TWI823895B (zh) | 抗b7-h4抗體、其抗原結合片段及其醫藥用途 | |
WO2017049452A1 (zh) | 抗人cd137的完全人抗体及其应用 | |
WO2018161872A1 (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
CN107428838B (zh) | 结合tfpi的新型抗体以及包含所述抗体的组合物 | |
CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
CN113508139A (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
CN114206941A (zh) | 抗her2/抗4-1bb双特异性抗体及其用途 | |
CA3206835A1 (en) | Mesothelin binding molecule and application thereof | |
CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
CN111344305B (zh) | 抗pd-l1的抗体及其用途 | |
CN114667296B (zh) | 一种双特异性抗体及其用途 | |
JP7245358B2 (ja) | 抗cd25抗体及びその適用 | |
JP2022550121A (ja) | Lifに特異的な結合分子及びその使用 | |
WO2023051656A1 (zh) | 双特异性抗体及其应用 | |
WO2024078558A1 (zh) | 抗cd100抗体及其用途 | |
KR20170076332A (ko) | 항 Ang2 항체를 포함하는 면역강화제 | |
JP2024509369A (ja) | 抗pd-l1抗体及びその使用 | |
TW202327649A (zh) | Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症 | |
CN116648461A (zh) | 新型抗-lag3抗体及其制备和使用方法 | |
CN116355096A (zh) | 重组抗人tigit抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20822451 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3135988 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021560523 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020290119 Country of ref document: AU Date of ref document: 20200608 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020822451 Country of ref document: EP Effective date: 20210924 |
|
ENP | Entry into the national phase |
Ref document number: 20217040151 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021024820 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112021024820 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211208 |